Nexentis Technologies' Subsidiary Receives U.S. Patent And Trademark Office Official Trademark Registration For Its MITOLINE Algorithm Platform

Nexentis Technologies Inc. (NASDAQ:NXTS), ("Nexentis" or the "Company"), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE.